drugset / Trial / NCT02099292
Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma
Phase 2
Completed
103 enrolled
Georg Hess, MD
Klinikum Frankfurt Höchst · collabRoche Pharma AG · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy in patients with relapsed/refractory aggressive and indolent lymphoma.
Timeline
- Start
- 2001-05
- Primary completion
- 2005-05
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 24 mg | Oral |
| Subject | Etoposide | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 140 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | carmustine | Small molecule | 60 mg/m2 | Intravenous |
| Subject | carmustine | Small molecule | 300 mg/m2 | Intravenous |